Back to Dashboard
ZYME · Healthcare

ZYMEWORKS INC

USA Healthcare Filing: 2025-12-31
Smart-money confidence · 1 of 3 sources firing
Bearish — money moving out

No standout activity across the feeds we track.

Hedge funds
26
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s.  ·  how the score works
◆ Next steps Interested in ZYMEWORKS INC? Here's what to do with it.
Not financial advice. Bogen Capital surfaces public SEC filings — you decide what to do with them.
Market cap
$1.7B
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqGS
About ZYMEWORKS INC

Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera…

Who's behind the signal
Every informed buyer we can see on ZYME, across all three feeds.
Hedge funds · 5
D.E. Shaw & Co Increased +76%
Citadel Advisors Increased +23%
AQR Capital Management Decreased −40%
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar. ZYMEWORKS INC isn't in the top-10 model right now, but 5 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
5
Investors
0
New positions
2
Increasing
3
Decreasing
0
Unchanged
Price History
Loading price data...
Return: High: Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.0×
Increased +76%
% of portfolio
0.0%
Position change
+76%
0.0% of D.E. Shaw & Co's portfolio
Trust weight: 1.0×
Increased +23%
% of portfolio
0.0%
Position change
+23%
0.0% of Citadel Advisors's portfolio
Trust weight: 1.0×
Decreased −66%
% of portfolio
0.0%
Position change
−66%
0.0% of Millennium Management's portfolio
Trust weight: 1.2×
Decreased −19%
% of portfolio
0.0%
Position change
−19%
0.0% of Tudor Investment's portfolio
Trust weight: 1.0×
Decreased −40%
% of portfolio
0.0%
Position change
−40%
0.0% of AQR Capital Management's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to ZYMEWORKS INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell ZYMEWORKS INC or any security.

Get the Weekly Update

Every Sunday, we'll send you what Buffett, Dalio, Ackman and 47 other legendary investors are buying — free, straight from their SEC filings.
Free forever · No spam · Unsubscribe anytime